This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Cardiopulmonary Disease Diagnostics and Treatment Market over the forecast period.
The global cardiopulmonary disease diagnostics market is expected to grow significantly at an alluring CAGR over the predicted years (2018-2023). Cardiopulmonary disease (COPD) is a medical term that is used for describing different chronic disorders which affect the heart (cardio) as well as the lung (pulmonary). It is a universal or umbrella term for the conditions that affect the blood vessels or heart. Generally, it is associated to the building-up of fatty deposits in the arteries which is known as the atherosclerosis. COPD can be associated with artery damage in organs such as the eyes, kidneys, heart and brain. Cardiopulmonary diseases at all times do not show noticeable symptoms but some of its signs could be nausea, sweating, chest pain, dizziness and shortness of breath. Some of the common causes of COPD include exposure to irritants for a long-term which damage the airways and lungs, exposure to dust that is work-related, indoor air pollutants and second-hand smoke. The emergence of vapers or e-cigarettes along with other form of latest tobacco products which produce nicotine aerosolized in different solvents are raising critical queries pertaining to the prospective risk for COPD amid users.
There are a couple of factors that is driving the growth of the cardiopulmonary disease diagnostics market. Some of the market trends and factors in this market as per an analysis conducted by Market Research Future (MRFR) include growing health disorders associated to the heart and lungs, rise in aged population, high awareness amid physicians and patients, effective healthcare infrastructure, advanced healthcare facilities, rise in modern technological equipment to diagnose COPD and better reimbursement policies. But on the flip side, the high treatment cost and the government’s regulatory nature on the pharmaceutical companies may hinder the growth of the cardiopulmonary disease diagnostics market.
Market Research Future report provides a comprehensive segmental analysis of the cardiopulmonary disease diagnostics market on the basis of disease type, type and end-users.
Based on disease type, it is segmented into respiratory and cardiovascular diseases. The cardiovascular diseases are further segmented into hypertension, dysrhythmia, myocardial infarction, angina pectoris, coronary artery and others. The respiratory diseases are further segmented into cystic fibrosis, emphysema, bronchitis, asthma, influenza and others.
Based on type, the cardiopulmonary disease diagnostics market is segmented into treatment and diagnosis. The diagnosis segment is further segmented into spirometry, pulse oximeters, stress blood pressure monitors, single-photon emission computed tomography (SPECT), cardiac magnetic resonance imaging (MRI), cardiac computerized tomography (CT) scan, cardiac catheterization, stress test, echocardiogram, Holter monitoring and an electrocardiogram (ECG). The treatment segment is further segmented into medications which is again segmented into antiplatelet agents, anticoagulants, angiotensin II receptor blockers (ARBS) and angiotensin-converting enzyme (ACE) inhibitors.
Based on end-users, it is segmented into research institutes, rehab centers, specialty clinics, diagnostic centers, clinics and hospitals.
Based on region, the cardiopulmonary disease diagnostics market covers growth opportunities and latest trends across North America, Europe, Asia-Pacific, and the Middle East and Africa. Of these, North America is anticipated to govern the market during the predicted years owing to smoking habits, change in lifestyle, rise in disposal income, medical tourism, technological advancement and rising healthcare awareness. Europe is likely to grab the second position with COPD diagnostics and treatment being quite common in this region. The other reasons that is likely to propel the growth of the cardiopulmonary disease diagnostics market here include rise in heart rhythm problems, diabetes and rise in elderly population. The market in the APAC region is likely to grow at the fastest pace during the predicted years owing to growing elderly population, changing lifestyle and increasing patient population. On the other hand, the Middle East and Africa will account for a minimum share in the market owing to low per capita income and stringent government policies.
Leading players profiled in the cardiopulmonary disease diagnostics market include Vyaire Medical Inc, Masimo Corporation, Schiller AG, NIHON KOHDEN CORPORATION, MGC Diagnostics Corporation, Koninklijke Philips N.V., Hill-Rom Holdings, Inc., Halma plc, Cosmed Medical, GE Healthcare and Cardinal Health.
Dec 2018- The research team at Wayne State University in association with Arterez, LLC has suggested a clinical study for identifying the diagnostic accuracy and fingerprint of Arterez’s glycocalyx biomarkers in association to arterial disease, particularly heart failure and hypertension.